Scott E. McNeil
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Scott E. McNeil has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Jeffrey D. Clogston
Nanotechnology Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA
3 shared publications Anil K. Patri
Nanotechnology Characterization Laboratory, Advanced Technology Program, SAIC-Frederick, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702
2 shared publicationsMarina A. Dobrovolskaia
Nanotechnology Characterization Laboratory, Advanced Technology Program, SAIC-Frederick Inc., NCI-Frederick, Frederick, MD 21702, USA
2 shared publications- Rachael M. Crist
Nanotechnology Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA
2 shared publications Barry W. Neun
Nanotechnology Characterization Laboratory, Advanced Technology Program, SAIC-Frederick Inc., NCI-Frederick, Frederick, Maryland 21702
1 shared publication- Giulio F. Paciotti
CytImmune Sciences, 9640 Medical Center Drive, Rockville, MD 20850, USA
1 shared publication
Latest Publications
- 17 October 2017
- Published by Springer Nature
- Vol. 1682, 3-16
Evaluating Nanomedicines: Obstacles and Advancements
Continued advancements in nanotechnology are expanding the boundaries of medical research, most notably as drug delivery agents for treatment against cancer. Drug delivery with nanotechnology can offer greater control over the biodistribution of therapeutic agents to improve the therapeutic index. In the last 20 years, a number of nanomedicines have transitioned into the clinic. As nanomedicines evolve, techniques to properly evaluate their safety and efficacy must also evolve. Characterization methods for nano-based materials must be adapted to the demands of nanomedicine developers and regulators. This second edition book provides updated characterization protocols designed to address the clinical potential of nanomedicines during their preclinical development. In this chapter, the characterization challenges of nanoparticles intended for drug delivery will be discussed, along with examples of advancements and improvements in nanomedicine characterization.
- 17 October 2017
- Published by Springer Nature
- Vol. 1682, 3-16
Evaluating Nanomedicines: Obstacles and Advancements
Continued advancements in nanotechnology are expanding the boundaries of medical research, most notably as drug delivery agents for treatment against cancer. Drug delivery with nanotechnology can offer greater control over the biodistribution of therapeutic agents to improve the therapeutic index. In the last 20 years, a number of nanomedicines have transitioned into the clinic. As nanomedicines evolve, techniques to properly evaluate their safety and efficacy must also evolve. Characterization methods for nano-based materials must be adapted to the demands of nanomedicine developers and regulators. This second edition book provides updated characterization protocols designed to address the clinical potential of nanomedicines during their preclinical development. In this chapter, the characterization challenges of nanoparticles intended for drug delivery will be discussed, along with examples of advancements and improvements in nanomedicine characterization.
- 1 January 2016
- Published by Springer Nature
- p. 187-203
Physicochemical Characterization of Polymer Nanoparticles: Challenges and Present Limitations
- 1 January 2016
- Published by Springer Nature
- p. 187-203
Physicochemical Characterization of Polymer Nanoparticles: Challenges and Present Limitations
- 1 December 2013
- Published by Elsevier in Journal of Controlled Release
- Vol. 172 (2) , 456-466
Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines
- 1 December 2013
- Published by Elsevier in Journal of Controlled Release
- Vol. 172 (2) , 456-466
Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines
- 6 July 2012
- Published by Oxford University Press (OUP) in Integrative Biology
- Vol. 5 (1) , 66-73
Common pitfalls in nanotechnology: lessons learned from NCI's Nanotechnology Characterization Laboratory
The NCL discusses many of the complexities associated with nanoparticle synthesis, purification, characterization and analysis.
- 6 July 2012
- Published by Oxford University Press (OUP) in Integrative Biology
- Vol. 5 (1) , 66-73
Common pitfalls in nanotechnology: lessons learned from NCI's Nanotechnology Characterization Laboratory
The NCL discusses many of the complexities associated with nanoparticle synthesis, purification, characterization and analysis.
- 19 October 2010
- Published by Springer Nature
- Vol. 697, 9-15
Challenges for Nanoparticle Characterization
The Food and Drug Administration (FDA) and pharmaceutical industry have used standards to assess material biocompatibility, immunotoxicity, purity, and sterility (as well as many other properties) for several decades. Nanoparticle developers and manufacturers leverage well-established methods as much as possible. However, the unique properties of nanomaterials often interfere with standardized protocols, giving false-positive or false-negative results. This chapter provides details of some of the problems which can arise during the characterization of nanoparticle samples. Additionally, we discuss ways to identify, avoid, and resolve such interference, with emphasis on the use of inhibition and enhancement controls.
- 19 October 2010
- Published by Springer Nature
- Vol. 697, 9-15
Challenges for Nanoparticle Characterization
The Food and Drug Administration (FDA) and pharmaceutical industry have used standards to assess material biocompatibility, immunotoxicity, purity, and sterility (as well as many other properties) for several decades. Nanoparticle developers and manufacturers leverage well-established methods as much as possible. However, the unique properties of nanomaterials often interfere with standardized protocols, giving false-positive or false-negative results. This chapter provides details of some of the problems which can arise during the characterization of nanoparticle samples. Additionally, we discuss ways to identify, avoid, and resolve such interference, with emphasis on the use of inhibition and enhancement controls.
- 19 October 2010
- Published by Springer Nature
- Vol. 697, 3-8
Unique Benefits of Nanotechnology to Drug Delivery and Diagnostics
Nanotechnology offers many potential benefits to medical research by making pharmaceuticals more efficacious and by decreasing their adverse side-effects. Preclinical characterization of nanoparticles intended for medical applications is complicated – due to the variety of materials used, their unique surface properties and multifunctional nature. This chapter serves as an introduction to the volume, giving a broad overview of applications of nanotechnology to medicine, and describes some of the beneficial aspects of nanotechnology-based drug delivery. We define nanotechnology and provide brief descriptions of the major classes of nanomaterials used for medical applications. The following two chapters discuss scientific and regulatory hurdles involved in the use of nanotechnology in medicine. The remaining bulk of the volume provides the reader with protocols that have been tested against clinically relevant nanoparticles and describes some of the nuances of nanoparticle types and necessary controls.
- 19 October 2010
- Published by Springer Nature
- Vol. 697, 3-8
Unique Benefits of Nanotechnology to Drug Delivery and Diagnostics
Nanotechnology offers many potential benefits to medical research by making pharmaceuticals more efficacious and by decreasing their adverse side-effects. Preclinical characterization of nanoparticles intended for medical applications is complicated – due to the variety of materials used, their unique surface properties and multifunctional nature. This chapter serves as an introduction to the volume, giving a broad overview of applications of nanotechnology to medicine, and describes some of the beneficial aspects of nanotechnology-based drug delivery. We define nanotechnology and provide brief descriptions of the major classes of nanomaterials used for medical applications. The following two chapters discuss scientific and regulatory hurdles involved in the use of nanotechnology in medicine. The remaining bulk of the volume provides the reader with protocols that have been tested against clinically relevant nanoparticles and describes some of the nuances of nanoparticle types and necessary controls.
- 1 September 2010
- Published by Elsevier in Journal of Controlled Release
- Vol. 146 (2) , 164-174
Translational considerations for cancer nanomedicine
- 1 September 2010
- Published by Elsevier in Journal of Controlled Release
- Vol. 146 (2) , 164-174
Translational considerations for cancer nanomedicine
- 13 January 2009
- Published by Wiley in WIREs Nanomedicine and Nanobiotechnology
- Vol. 1 (3) , 264-271
Nanoparticle therapeutics: a personal perspective
Nanotechnology offers many potential benefits to cancer research through passive and active targeting, increased solubility/bioavailablility, and novel therapies. However, preclinical characterization of nanoparticles is complicated by the variety of materials, their unique surface properties, reactivity, and the task of tracking the individual components of multicomponent, multifunctional nanoparticle therapeutics in in vivo studies. There are also regulatory considerations and scale‐up challenges that must be addressed. Despite these hurdles, cancer research has seen appreciable improvements in efficacy and quite a decrease in the toxicity of chemotherapeutics because of ‘nanotech’ formulations, and several engineered nanoparticle clinical trials are well underway. This article reviews some of the challenges and benefits of nanomedicine for cancer therapeutics and diagnostics. © 2009 John Wiley & Sons, Inc.This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies
- 13 January 2009
- Published by Wiley in WIREs Nanomedicine and Nanobiotechnology
- Vol. 1 (3) , 264-271
Nanoparticle therapeutics: a personal perspective
Nanotechnology offers many potential benefits to cancer research through passive and active targeting, increased solubility/bioavailablility, and novel therapies. However, preclinical characterization of nanoparticles is complicated by the variety of materials, their unique surface properties, reactivity, and the task of tracking the individual components of multicomponent, multifunctional nanoparticle therapeutics in in vivo studies. There are also regulatory considerations and scale‐up challenges that must be addressed. Despite these hurdles, cancer research has seen appreciable improvements in efficacy and quite a decrease in the toxicity of chemotherapeutics because of ‘nanotech’ formulations, and several engineered nanoparticle clinical trials are well underway. This article reviews some of the challenges and benefits of nanomedicine for cancer therapeutics and diagnostics. © 2009 John Wiley & Sons, Inc.This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies
- 8 July 2008
- Published by American Chemical Society (ACS) in Nano Letters
- Vol. 8 (8) , 2180-2187
Method for Analysis of Nanoparticle Hemolytic Properties in Vitro
Hemolysis (destruction of red blood cells) in vivo can lead to anemia, jaundice, and other pathological conditions; therefore the hemolytic potential of all intravenously administered pharmaceuticals must be evaluated. Nanotechnology-derived devices and drug carriers are emerging as alternatives to conventional small-molecule drugs, and in vitro evaluation of their biocompatibility with blood components is a necessary part of early preclinical development. The small size and unique physicochemical properties of nanoparticles may cause their interactions with erythrocytes to differ from those observed for conventional pharmaceuticals and may also cause interference with standardized in vitro tests. Separating true hemolytic responses from the false-positive or false-negative results caused by particle interference is important for correct interpretation of these tests. Here we describe validation of an in vitro assay for the analysis of nanoparticle hemolytic properties and discuss observed nanointerferences with the assay. We propose alternative methods to avoid misleading results from nanoparticles and discuss the potential relevance of nanoparticle in vitro hemolytic properties to in vivo systems.
- 8 July 2008
- Published by American Chemical Society (ACS) in Nano Letters
- Vol. 8 (8) , 2180-2187
Method for Analysis of Nanoparticle Hemolytic Properties in Vitro
Hemolysis (destruction of red blood cells) in vivo can lead to anemia, jaundice, and other pathological conditions; therefore the hemolytic potential of all intravenously administered pharmaceuticals must be evaluated. Nanotechnology-derived devices and drug carriers are emerging as alternatives to conventional small-molecule drugs, and in vitro evaluation of their biocompatibility with blood components is a necessary part of early preclinical development. The small size and unique physicochemical properties of nanoparticles may cause their interactions with erythrocytes to differ from those observed for conventional pharmaceuticals and may also cause interference with standardized in vitro tests. Separating true hemolytic responses from the false-positive or false-negative results caused by particle interference is important for correct interpretation of these tests. Here we describe validation of an in vitro assay for the analysis of nanoparticle hemolytic properties and discuss observed nanointerferences with the assay. We propose alternative methods to avoid misleading results from nanoparticles and discuss the potential relevance of nanoparticle in vitro hemolytic properties to in vivo systems.